A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)
- Conditions
- Systemic Sclerosis With and Without Interstitial Lung Disease
- Interventions
- Biological: PlaceboBiological: MK-2225
- Registration Number
- NCT04948554
- Lead Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Brief Summary
The purpose of the MK-2225-002 (A1334-02) study is to evaluate the safety and tolerability of MK-2225 (ACE-1334) plus standard of care (SOC) in participants with Systemic Sclerosis (SSc) following multiple doses.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 5
-
Participants must have SSc, as defined using the 2013 American College of Rheumatology/European League Against Rheumatism criteria
-
If participant is on a non-excluded immunosuppressive therapy (e.g. mycophenolate, methotrexate, azathioprine, etc.) the dose should be stable for > 2 months at the time of screening
-
Women of childbearing potential must:
- If sexually active, have used, and agree to use, highly effective contraception without interruption, for at least 28 days prior to starting investigational product, during the study (including dose interruptions), and for 17 weeks (119 days) after discontinuation of study treatment
- Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 17 weeks (119 days) after the last dose of study treatment
-
Male participants must:
- Agree to use a condom, defined as a male latex condom or nonlatex condom NOT made out of natural (animal) membrane (e.g., polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions, and for at least 17 weeks (119 days) following investigational product discontinuation, even if he has undergone a successful vasectomy
- Refrain from donating blood or sperm for the duration of the study and for 17 weeks (119 days) after the last dose of study treatment
-
Must agree to not participate in any other study of investigational drugs/devices while enrolled in this study
- Participant with SSc-pulmonary arterial hypertension (PAH) (except those participants with mild PAH on up to 2 oral drugs and mean pulmonary arterial pressure < 30 mmHg or low risk by risk calculator)
- In the opinion of the investigator, other clinically significant pulmonary abnormalities (such as obstructive lung disease, asthma, etc.)
- Other investigational therapy received within 1 month or 6 half-lives (whichever is greater) prior to the Screening Visit
- Prior exposure to MK-2225 or other TGF-β antibodies or any TGF-β family targeted biologic or hypersensitivity to the components of MK-2225
- Hypersensitivity to placebo or any of its components
- Previous hematopoietic stem cell transplantation (HSCT) or HSCT planned within the next year
- Major surgical procedures planned during the study period
- Oral prednisone or equivalent > 10 mg/day
- Participant with history of gastric antral vascular ectasia or gastrointestinal bleed
- On anticoagulation therapy (such as prophylaxis anticoagulation, warfarin, direct thrombin inhibitors or other including low molecular weight subcutaneous or intravenous therapeutic heparin), or antiplatelet therapy including aspirin. Use of fish oil supplements within 2 weeks prior to randomization and throughout study is not permitted.
- History of any other medical condition that might interfere with a participant's ability to participate in the study
- Active clinically significant viral, bacterial, or fungal infection, or any episode of infection requiring hospitalization within 4 weeks prior to screening
- Use of cyclophosphamide ≤ 6 months from screening
- Use of nintedanib or pirfenidone ≤ 28 days from screening
- Recent scleroderma renal crisis < 6 months before screening
- Use of tocilizumab ≤ 2 months from screening
- Has received any nonlive vaccine starting from 14 days prior to study intervention or is scheduled to receive any nonlive vaccine through 30 days following study intervention. Exception: COVID-19 vaccine may be administered.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Cohort 3: Placebo Placebo Participants in Cohort 3 will receive placebo Q2W plus SOC for 12 weeks. Cohort 4: Placebo Placebo Participants in Cohort 4 will receive placebo Q2W plus SOC for 12 weeks. Cohort 4: MK-2225 MK-2225 Participants in Cohort 4 will receive MK-2225 at ≤2.0 mg/kg Q2W if needed plus SOC for 12 weeks. Cohort 6: MK-2225 MK-2225 Participants in Cohort 6 will receive MK-2225 (no more frequent than Q2W) ≤2.25 mg/kg Q2W or ≤4.5 mg/kg Q4W if needed plus SOC for 12 weeks. Cohort 1: MK-2225 MK-2225 Participants in Cohort 1 will receive MK-2225 at 0.25 mg/kg once every two weeks (Q2W) plus standard of care (SOC) for 12 weeks. Cohort 1: Placebo Placebo Participants in Cohort 1 will receive placebo Q2W plus SOC for 12 weeks. Cohort 2: Placebo Placebo Participants in Cohort 2 will receive placebo Q2W plus SOC for 12 weeks. Cohort 5: MK-2225 MK-2225 Participants in Cohort 5 will receive MK-2225 (no more frequent than Q2W) ≤2.25 mg/kg Q2W or ≤4.5 mg/kg Q4W if needed plus SOC for 12 weeks. Cohort 5: Placebo Placebo Participants in Cohort 5 will receive (no more frequent than Q2W) placebo plus SOC for 12 weeks. Cohort 2: MK-2225 MK-2225 Participants in Cohort 2 will receive MK-2225 at 0.5 mg/kg (or lower) Q2W plus SOC for 12 weeks. Cohort 3: MK-2225 MK-2225 Participants in Cohort 3 will receive MK-2225 at 1.0 mg/kg (or lower) Q2W plus SOC for 12 weeks. Cohort 6: Placebo Placebo Participants in Cohort 6 will receive (no more frequent than Q2W) placebo plus SOC for 12 weeks.
- Primary Outcome Measures
Name Time Method Number of Participants with ≥1 Adverse Event (AE) Up to 20 Weeks An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE will be reported.
Number of Participants Discontinuing from Study Therapy Due to AE Up to 12 Weeks An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE will be reported.
- Secondary Outcome Measures
Name Time Method Serum Maximum Concentration (Cmax) of MK-2225 Up to 12 Weeks Cmax is the maximum concentration of the drug observed in plasma. Blood samples will be collected at designated timepoints to determine Cmax of MK-2225.
Time to peak Serum Concentration (Tmax) of MK-2225 Up to 12 Weeks Tmax is the amount of time required to reach Cmax. Blood samples will be collected at designated timepoints to determine Tmax of MK-2225.
Area Under the Concentration-Time Curve (AUC0-tau) of MK-2225 Up to 12 Weeks AUC0-tau is the area under the concentration-time curve. Blood samples will be collected at designated timepoints to determine AUC0-tau of MK-2225.
Serum Apparent Terminal Half-Life (t1/2) of MK-2225 Up to 12 Weeks t1/2 is the time required for 50% of drug to be cleared from serum. Blood samples will be collected at designated timepoints to determine t1/2 of MK-2225.
Accumulation ratio of AUCtau (RAUC) Up to 12 Weeks RAUC is the accumulation ratio of AUCtau after multiple doses relative to after a single dose. Blood samples will be collected at designated timepoints to determine RAUC of MK-2225.
Trial Locations
- Locations (16)
Central Florida Pulmonary Group ( Site 1005)
🇺🇸Orlando, Florida, United States
University of Kansas Medical Center ( Site 1007)
🇺🇸Kansas City, Kansas, United States
Azienda Ospedaliero Universitaria Careggi (Site 1401)
🇮🇹Florence, Tuscany, Italy
Keck Medical Center ( Site 1001)
🇺🇸Los Angeles, California, United States
Kantonsspital St. Gallen (Site 1301)
🇨🇭St Gallen, Sankt Gallen, Switzerland
West Tennessee Research Institute ( Site 1012)
🇺🇸Jackson, Tennessee, United States
Penn State Milton S Hershey Medical Center ( Site 1004)
🇺🇸Hershey, Pennsylvania, United States
Metroplex Clinical Research Center ( Site 1018)
🇺🇸Dallas, Texas, United States
University of Florida ( Site 1002)
🇺🇸Gainesville, Florida, United States
Hôpital Neuchatelois ( Site 1304)
🇨🇭Neuchâtel, Neuchâtel (fr), Switzerland
Mount Sinai Hospital ( Site 1101)
🇨🇦Toronto, Ontario, Canada
Georgetown University Medical Center ( Site 1010)
🇺🇸Washington, District of Columbia, United States
Azienda Ospedaliera Universitaria Integrata Di Verona ( Site 1402)
🇮🇹Verona, Veneto, Italy
The Cleveland Clinic Foundation ( Site 1003)
🇺🇸Cleveland, Ohio, United States
UCSD Altman Clinical and Translational Research Institute (Site 1013)
🇺🇸La Jolla, California, United States
Medster Research, LLC ( Site 1017)
🇺🇸Valdosta, Georgia, United States